title: The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.
abstract: High-grade ovarian serous carcinomas (HGSC) are characterized by TP53 mutations and non-random patterns of chromosomal anomalies, where the nature of the TP53 mutation may correlate with clinical outcome. However, the frequency of common somatic genomic events occurring in HGSCs from demographically defined populations has not been explored. Whole genome SNP array, and TP53 mutation, gene and protein expression analyses were assessed in 87 confirmed HGSC samples with clinical correlates from French Canadians, a population exhibiting strong founder effects, and results were compared with independent reports describing similar analyses from unselected populations. TP53 mutations were identified in 91% of HGSCs. Anomalies observed in more than 50% of TP53 mutation-positive HGSCs involved gains of 3q, 8q and 20q, and losses of 4q, 5q, 6q, 8p, 13q, 16q, 17p, 17q, 22q and Xp. Nearly 400 regions of non-overlapping amplification or deletion were identified, where 178 amplifications and 98 deletions involved known genes. The subgroup expressing mutant p53 protein exhibited significantly prolonged overall and disease-free survival as compared with the p53 protein null subgroup. Interestingly, a comparative analysis of genomic landscapes revealed a significant enrichment of gains involving 1q, 8q, and 12p intervals in the subgroup expressing mutant p53 protein as compared with the p53 protein null subgroup. Although the findings show that the frequency of TP53 mutations and the genomic landscapes observed in French Canadian samples were similar to those reported for samples from unselected populations, there were differences in the magnitude of global gains/losses of specific chromosomal arms and in the spectrum of amplifications and deletions involving focal regions in individual samples. The findings from our comparative genomic analyses also support the notion that there may be biological differences between HGSCs that could be related to the nature of the TP53 mutation.
authors.affiliation: Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
authors.forename: Paulina M
authors.initials: PM
authors.lastname: Wojnarowicz
authors.forename: Kathleen Klein
authors.initials: KK
authors.lastname: Oros
authors.forename: Michael C J
authors.initials: MC
authors.lastname: Quinn
authors.forename: Suzanna L
authors.initials: SL
authors.lastname: Arcand
authors.forename: Karen
authors.initials: K
authors.lastname: Gambaro
authors.forename: Jason
authors.initials: J
authors.lastname: Madore
authors.forename: Ashley H
authors.initials: AH
authors.lastname: Birch
authors.forename: Manon
authors.initials: M
authors.lastname: de Ladurantaye
authors.forename: Kurosh
authors.initials: K
authors.lastname: Rahimi
authors.forename: Diane M
authors.initials: DM
authors.lastname: Provencher
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Mes-Masson
authors.forename: Celia M T
authors.initials: CM
authors.lastname: Greenwood
authors.forename: Patricia N
authors.initials: PN
authors.lastname: Tonin
mesh_terms: D002170:Canada; D002869:Chromosome Aberrations; D055028:Comparative Genomic Hybridization; D018284:Cystadenocarcinoma, Serous / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D005260:Female; D018703:Founder Effect; D011905:Genes, ras; D006801:Humans; D009154:Mutation; D060787:Neoplasm Grading; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D020641:Polymorphism, Single Nucleotide; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism
chemical_list: D016159:Tumor Suppressor Protein p53; D048493:Proto-Oncogene Proteins B-raf